Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	1/11/2005 10:36:32 AM
	of 3044

Millennium Pharmaceuticals "neutral," target price reduced Tuesday, January 11, 2005 7:05:09 AM ET Robert W. Baird NEW YORK, January 11 (newratings.com) - Analysts at Robert W Baird maintain their "neutral" rating on Millennium Pharmaceuticals (MLNM.NAS), while revising their estimates for the company. The target price has been reduced from $15 to $13. In a research note published this morning, the analysts mention that the company reported its 4Q04 revenues short of the estimates and the consensus due to the weaker-than-expected sales of its Velcade and Integrilin drugs. Robert W Baird believes, however, that the commercial prospects of Millennium Pharmaceuticals’ Velcade and Integrilin drugs would improve this year. The EPS estimate for 2004 has been reduced from -$0.55 to -$0.56. The EPS estimate for 2005 has been raised from -$0.33 to -$0.32.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next